$243 Million is the total value of Fairmount Funds Management LLC's 19 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 9.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INSM | Buy | INSMED INC | $36,539,000 | +11.5% | 1,283,887 | +33.5% | 15.02% | +8.8% |
| ZGNX | Buy | ZOGENIX INC | $34,046,000 | +24.1% | 1,970,259 | +40.2% | 14.00% | +21.1% |
| AXSM | Buy | AXSOME THERAPEUTICS INC | $21,088,000 | +48.0% | 312,598 | +24.2% | 8.67% | +44.4% |
| ARGX | Buy | ARGENX SEsponsored adr | $20,817,000 | +46.9% | 69,144 | +34.4% | 8.56% | +43.3% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $13,163,000 | -26.5% | 505,890 | -10.6% | 5.41% | -28.3% |
| TIL | Buy | INSTIL BIO INC | $13,020,000 | -5.6% | 673,905 | +22.5% | 5.35% | -7.9% |
| ALLK | Buy | ALLAKOS INC | $12,990,000 | -23.4% | 152,162 | +3.0% | 5.34% | -25.2% |
| COGT | COGENT BIOSCIENCES INC | $12,643,000 | -7.6% | 1,558,975 | 0.0% | 5.20% | -9.9% | |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $11,096,000 | +11.1% | 2,533,237 | +57.5% | 4.56% | +8.4% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $10,337,000 | -7.3% | 423,817 | -2.0% | 4.25% | -9.6% |
| RACA | Buy | THERAPEUTICS ACQUISITION COR | $8,875,000 | +1587.3% | 864,214 | +1628.4% | 3.65% | +1543.7% |
| Sell | TRILLIUM THERAPEUTICS INC | $8,694,000 | -38.8% | 896,281 | -32.3% | 3.57% | -40.3% | |
| Buy | CATABASIS PHARMACEUTICALS IN | $8,634,000 | +5506.5% | 4,092,166 | +7597.0% | 3.55% | +5361.5% | |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $8,570,000 | +9.9% | 888,980 | +12.7% | 3.52% | +7.2% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $7,836,000 | -7.2% | 178,058 | +4.0% | 3.22% | -9.4% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $7,354,000 | +3.1% | 210,000 | +20.0% | 3.02% | +0.6% |
| KROS | Buy | KEROS THERAPEUTICS INC | $6,342,000 | -5.8% | 149,333 | +36.6% | 2.61% | -8.1% |
| VRDN | VIRIDIAN THERAPEUTICS INC | $642,000 | +10.5% | 35,092 | 0.0% | 0.26% | +7.8% | |
| VRNA | VERONA PHARMA PLCsponsored ads | $549,000 | -21.8% | 83,944 | 0.0% | 0.23% | -23.6% | |
| MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -353,016 | -100.0% | -3.06% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -67,800 | -100.0% | -4.90% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.